P14 Performance of PCA3 and TMPRSS2:ERG within the prostate cancer prevention trial risk calculator version 2 in a Lithuanian cohort
Saved in:
| Main Authors: | J. Kemesiene, G. Cholstauskas, C. Nicolau, K. Zviniene, M. Lopeta, S. Veneviciute, I. Asmenaviciute, K. Tamosauskaite, I. Pikuniene, M. Jievaltas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-07-01
|
| Series: | European Urology Open Science |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S266616832500165X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Performance of PCA3 and TMPRSS2:ERG Within the Prostate Cancer Prevention Trial Risk Calculator Version 2 in a Lithuanian Cohort
by: Kemesiene J, et al.
Published: (2025-03-01) -
Exploring therapeutic applications of PTEN, TMPRSS2:ERG fusion, and tumour molecular subtypes in prostate cancer management
by: Fidelis Charles Bugoye, et al.
Published: (2025-03-01) -
The Association of the Long Prostate Cancer Expressed PDE4D Transcripts to Poor Patient Outcome Depends on the Tumour’s TMPRSS2-ERG Fusion Status
by: Dianne van Strijp, et al.
Published: (2019-01-01) -
Bridging Cancer and COVID‐19: The Complex Interplay of ACE2 and TMPRSS2
by: Xuerui Tang, et al.
Published: (2025-04-01) -
Exploring TMPRSS2 Drug Target to Combat Influenza and Coronavirus Infection
by: Krishnaprasad Baby, et al.
Published: (2025-01-01)